According to Nymox Pharmaceutical's latest financial reports the company's current earnings are N/A. In 2022 the company made an earning of -A$10.61 Million, an increase over its 2021 earnings that were of -A$20.29 Million. The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -A$3.35 Million | -68.45% |
2022 | -A$10.61 Million | -47.71% |
2021 | -A$20.29 Million | 6.61% |
2020 | -A$19.03 Million | -10.91% |
2019 | -A$21.36 Million | 24.24% |
2018 | -A$17.19 Million | -20.03% |
2017 | -A$21.49 Million | 2.71% |
2016 | -A$20.93 Million | -63.86% |
2015 | -A$57.9 Million | 674.44% |
2014 | -A$7.48 Million | -6.11% |
2013 | -A$7.97 Million | -35.66% |
2012 | -A$12.38 Million | -20.76% |
2011 | -A$15.62 Million | 38.33% |
2010 | -A$11.3 Million | 35.59% |
2009 | -A$8.33 Million | 11.8% |
2008 | -A$7.45 Million | -12.94% |
2007 | -A$8.56 Million | 8.85% |
2006 | -A$7.86 Million | 36.5% |
2005 | -A$5.76 Million | -4.4% |
2004 | -A$6.03 Million | -14.58% |
2003 | -A$7.06 Million | |
2001 | -A$5.18 Million | -20.54% |
2000 | -A$6.52 Million | 21.72% |
1999 | -A$5.35 Million | -25.56% |
1998 | -A$7.19 Million | 101.3% |
1997 | -A$3.57 Million |